<DOC>
	<DOCNO>NCT01688895</DOCNO>
	<brief_summary>The initial objective protocol assemble well-documented group patient confirm diagnosis erythropoietic protoporphyrias , include autosomal recessive Erythropoietic Protoporphyria ( EPP ) X-Linked Protoporphyria ( XLP ) clinical , biochemical , genetic study . The long-term objective ( 1 ) conduct longitudinal investigation natural history , complication , therapeutic outcome people erythropoietic protoporphyria , ( 2 ) systematically investigate psychological effect erythropoietic protoporphyrias child adult , ( 3 ) investigate correlation identify genotype result clinical presentation , also determine possible interaction genetic marker .</brief_summary>
	<brief_title>Erythropoietic Protoporphyrias : Studies Natural History , Genotype-Phenotype Correlations , Psychosocial Impact</brief_title>
	<detailed_description>The porphyria group rare metabolic disease may present childhood adult life due deficiency enzymes heme biosynthetic pathway . The common manifestation related accumulation intermediate pathway usually occur acute neurological attack ( acute hepatic porphyria ) , cutaneous photosensitivity ( cutaneous porphyria , include erythropoietic protoporphyrias ) . Multiple mutation identify porphyrias [ Anderson , 2001 ] . The risk disability death disorder significant , part diagnosis often delay due lack adoption diagnostic test clinical practice . Moreover , natural history disorder well describe know determines difference outcomes . New therapy need . For exist therapy , high-quality evidence short long term efficacy safety generally lack [ Sood 2008 ] . Therefore , purpose study large group patient EPP XLP provide good understanding natural history disorder , affect available therapy , aid develop new form treatment . Much data collect subject participant Longitudinal Study Porphyrias access study specific investigation erythropoietic protoporphyrias . To maximize information informative objective , additional data collect , include additional biochemical finding EPP-specific psychosocial parameter . The Office Rare Diseases ( ORD ) National Institutes Health ( NIH ) establish Rare Diseases Clinical Research Network ( RDCRN ) collaboration NIH Institutes currently fund 19 rare disease clinical research consortium one Data Management Coordinating Center . The Porphyrias Consortium create part RDCRN , study human porphyria . The Porphyrias Consortium consortium academic institution list participate institution table . All Centers Porphyrias Consortium participate study . Additional center may add funding available .</detailed_description>
	<mesh_term>Protoporphyria , Erythropoietic</mesh_term>
	<criteria>All subject must also enrol Longitudinal Study Porphyrias . Willing sign inform consent form Biochemical find A marked increase erythrocyte protoporphyrin [ total erythrocyte protoporphyrin &gt; 200 ug/dL , 1.5fold increase ( relative ULN 80 ug/dL ) ] , predominance free protoporphyrin ( 85100 % EPP 5085 % XLP ) . Molecular finding one following : 1 . A disease cause FECH mutation trans IVS348C &gt; T low expression FECH allele 2 . Two diseasecausing FECH mutation 3 . A gainoffunction ALAS2 Cterminal deletion/exon 11 mutation ( XLP ) . If mutation find subject fulfill criterion 13 eligible enrollment . case elevation porphyrin urine , plasma erythrocyte due disease ( i.e . secondary porphyrinuria porphyrinemia ) , liver bone marrow diseases [ Gibson 2000 ] . patient prior diagnosis porphyria document review exist medical record repeat biochemical DNA testing .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>erythropoietic</keyword>
	<keyword>protoporphyria</keyword>
	<keyword>cutaneous</keyword>
	<keyword>porphyria</keyword>
</DOC>